

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

IN THE CLAIMS: 1-20. (Canceled)

21. **(Currently Amended)** A biliquid foam comprising:
- from 100% to 98% by weight of a non polar liquid comprising a mineral oil, a siloxane, an emollient ester, a glyceride, a lanolin oil, a natural oil, oleyl alcohol, isoeicosane or isooctahexacontane, or mixtures thereof;~~other than a petroleum-derivative, paraffin or a liquid halogenated hydrocarbon~~ and
- from 2 to 88% by weight of a continuous phase polar liquid comprising a C₁-C₄ alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase,
- wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly (alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C₈ -C₂₄ fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.
22. **(Previously presented)** The biliquid foam as claimed in claim 21, wherein the amount of surfactant is about 1% by weight based on the total formulation.

23. (Previously presented) The biliquid foam as claimed in claim 22, wherein the surfactant comprises a hydrogenated castor oil/polyethylene glycol adduct containing from 40 to 60 ethoxy groups.

24. (Previously presented) The biliquid foam as claimed in claim 22, wherein the surfactant comprises a castor oil/poly (alkylene glycol) adduct containing 25 to 45 ethoxy groups.

25. CANCELLED

26. (Previously presented) The biliquid foam as claimed in claim 25, wherein the siloxane comprises dimethicone, cyclomethicone, dimethiconol, dimethicone copolyol, octamethylcyclotetrasiloxane, octamethylcyclo-pentasiloxane, decamethylcyclopentasiloxane, or mixtures thereof.

27. (Previously presented) The biliquid foam as claimed in claim 26, wherein the emollient ester is isopropyl isostearate, lanolate, myristate or palmitate, or octyl palmitate, or mixtures thereof.

28. (Previously presented) The biliquid foam as claimed in claim 21, wherein the surfactant comprises a hydrogenated castor oil/polyethylene glycol adduct containing from 40 to 60 ethoxy groups.

29. (Previously presented) The biliquid foam as claimed in claim 21, wherein the surfactant comprises a castor oil/poly (alkylene glycol) adduct containing 25 to 45 ethoxy groups.

30. (Previously presented) The biliquid foam as claimed in claim 21, wherein the polar liquid is aqueous and comprises from 70% to 99% by weight of the C₁ -C₄,

alcohol, liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof.

31. CANCELLED

32. CANCELLED

33. CANCELLED

34. (Previously presented) A stable dispersion comprising from 1 to 80% by weight of a biliquid foam as claimed in claim 21, and from 99 to 20% by weight of an aqueous gel.

35. (Previously presented) The stable dispersion as claimed in claim 34, wherein the aqueous gel constitutes from 50 to 99% by weight thereof.

36. (Previously presented) The stable dispersion as claimed in claim 34, wherein the aqueous gel comprises a colloidal polymer or gum suspended in water.

37. (Previously presented) The stable dispersion as claimed in claim 34 which includes therein at least one pharmaceutical or cosmetic compound therein.

38. (Withdrawn) A process for preparing a stable dispersion which comprises from 1 to 80% by weight of a biliquid foam as claimed in claim 21, and from 99 to 20% by weight of an aqueous gel, which process mixing together the biliquid foam and the aqueous gel.

39. (Withdrawn) A process as claimed in claim 38, wherein the stable dispersion also comprises a pharmaceutical compound.

40. (Withdrawn) A process as claimed in claim 39 in which the stable dispersion is in a topical form for application to the skin and contains a non steroidal anti-inflammatory drug, an anti-acne compound, anti-viral or anti-bacterial compound.

41. (Withdrawn) A process as claimed in claim 40 in which the stable dispersion is in the form of a transdermal delivery device or in a cream or gel preparation and which contains nicotine, estradiol, nitroglycerin, testosterone or scopolamine as the active ingredient.

42. (Withdrawn) A process as claimed in claim 38, wherein the stable dispersion also comprises a cosmetic compound.

43. (Withdrawn) A process as claimed in claim 42 in which the stable dispersion is an anti-cellulite cream or an aftershave lotion.

44. (Withdrawn) A process as claimed in claim 38, wherein the stable dispersion also comprises a disinfectant compound.